Inhibrx Biosciences reported asset growth of -27.29% for the quarter ended Jun 2026. These growth metrics cover 11 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||||
| Assets Growth (1y) | -41.29% | -17.92% | -20.26% | -18.97% | -27.29% | ||||||
| Assets (QoQ) | -13.88% | -18.78% | 34.23% | -12.58% | -16.33% | -17.46% | |||||
| Capital Expenditures Growth (1y)Capex Growth (1y) | -69.54% | -99.54% | -98.12% | -95.95% | |||||||
| Capital Expenditures (QoQ)Capex (QoQ) | 324.41% | -67.49% | 8.58% | -79.67% | -93.52% | 31.25% | |||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -45.09% | -17.76% | -22.02% | -18.60% | -28.54% | ||||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | -13.47% | -22.28% | 41.89% | -13.82% | -17.95% | -18.86% | |||||
| Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) | 69.54% | 99.54% | 98.12% | 97.17% | |||||||
| Cash from Investing Activities (QoQ)Cash from Investing (QoQ) | -324.41% | 67.49% | -8.58% | 79.67% | 93.52% | -31.25% | |||||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | 44.18% | 23.06% | 43.07% | 47.78% | -11.70% | 31.10% | |||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | -4.75% | -10.96% | 9.03% | 47.21% | -44.38% | 17.90% | 16.55% | -12.92% | 10.94% | ||
| EBITDA Margin Growth (1y) | -2.28M | -4.39M | 15.76M | ||||||||
| EBITDA Margin (QoQ) | 9.96M | 3.19M | |||||||||
| EBIT Growth (1y) | -289.22% | -2.12% | 43.45% | 41.89% | 82.98% | 27.75% | 38.06% | -17.38% | |||
| EBIT Growth (3y) | 8.04% | ||||||||||
| EBIT Margin Growth (1y) | -2.31M | -4.45M | 15.88M | ||||||||
| EBIT Margin (QoQ) | 9.93M | 3.31M | |||||||||
| EBIT (QoQ) | -10.86% | -92.66% | 16.38% | -117.95% | 70.92% | -6.69% | 14.07% | 36.16% | -23.45% | 8.54% | |
| EBT Growth (1y) | 4,049.27% | 15.30% | 47.96% | 44.97% | -101.54% | 19.62% | 31.40% | -27.90% | |||
| EBT Growth (3y) | 7.99% | ||||||||||
| EBT Margin Growth (1y) | 201.48M | -4.22M | -186.02M | ||||||||
| EBT Margin (QoQ) | 11.33M | 3.79M | |||||||||
| EBT (QoQ) | -10.08% | -77.60% | 14.42% | 2,460.58% | -102.36% | -9.12% | 9.51% | 33.85% | -23.05% | 6.87% | |
| EPS (Basic) Growth (1y) | 3,047.25% | 35.45% | 59.29% | 51.48% | -101.46% | 19.68% | 34.44% | -26.26% | |||
| EPS (Basic) Growth (3y) | 18.45% | ||||||||||
| EPS (Basic) (QoQ) | -1.88% | -80.82% | 27.35% | 2,302.33% | -102.23% | -14.03% | 13.41% | 33.84% | -22.96% | 6.92% | |
| EPS (Diluted) Growth (1y) | 3,009.83% | 35.45% | 59.79% | 51.48% | -101.48% | 19.68% | 33.63% | -26.26% | |||
| EPS (Diluted) Growth (3y) | 18.45% | ||||||||||
| EPS (Diluted) (QoQ) | -1.88% | -80.82% | 27.35% | 2,274.37% | -102.26% | -12.65% | 12.35% | 33.84% | -22.96% | 6.92% | |
| FCF Margin Growth (1y) | -4.00M | 5.63M | |||||||||
| FCF Margin (QoQ) | 4.26M | ||||||||||
| Free Cash Flow Growth (1y)FCF Growth (1y) | 44.55% | 27.42% | 44.03% | 48.86% | -10.83% | 31.13% | |||||
| Free Cash Flow (QoQ)FCF (QoQ) | -9.46% | -6.48% | 8.72% | 47.88% | -43.27% | 17.88% | 16.60% | -12.96% | 10.97% | ||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | -473.91% | -75.70% | 70.95% | 35.24% | |||||||
| Interest Coverage Ratio Growth (3y)Interest Cover Growth (3y) | -2.59% | ||||||||||
| Interest Coverage Ratio (QoQ)Interest Cover (QoQ) | -7.54% | -90.92% | 15.43% | -230.52% | 45.34% | -21.90% | 8.66% | ||||
| Net Cash Flow Growth (1y)NCF Growth (1y) | -121.08% | 26.37% | 351.26% | -16.90% | -9.67% | 33.99% | |||||
| Net Cash Flow (QoQ)NCF (QoQ) | -141.01% | 57.17% | -0.72% | -19.14% | -43.27% | 246.16% | -146.86% | -11.77% | 13.77% | ||
| Net Income Growth (1y) | 4,048.85% | 15.30% | 48.86% | 44.97% | -101.54% | 19.62% | 31.40% | -27.91% | |||
| Net Income Growth (3y) | 7.99% | ||||||||||
| Net Income (QoQ) | -10.07% | -80.74% | 15.91% | 2,460.58% | -102.36% | -9.12% | 9.51% | 33.84% | -23.04% | 6.87% | |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | 4,048.85% | 15.30% | 48.86% | 44.97% | -101.54% | 19.62% | 31.40% | -27.91% | |||
| Net Income towards Common Stockholders Growth (3y)Net Income Growth (3y) | 7.99% | ||||||||||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | -10.07% | -80.74% | 15.91% | 2,460.58% | -102.36% | -9.12% | 9.51% | 33.84% | -23.04% | 6.87% | |
| Net Margin Growth (1y) | 201.49M | -4.21M | -186.02M | ||||||||
| Net Margin (QoQ) | 11.33M | 3.78M | |||||||||
| Operating Income Growth (1y)Op. Inc Growth (1y) | -289.22% | -2.12% | 43.45% | 41.89% | 82.98% | 27.75% | 38.06% | -17.38% | |||
| Operating Income Growth (3y)Op. Inc Growth (3y) | 8.04% | ||||||||||
| Operating Income (QoQ)Op. Inc (QoQ) | -10.86% | -92.66% | 16.38% | -117.95% | 70.92% | -6.69% | 14.07% | 36.16% | -23.45% | 8.54% | |
| Operating Margin Growth (1y) | -2.31M | -4.45M | 15.88M | ||||||||
| Operating Margin (QoQ) | 9.93M | 3.31M | |||||||||
| Profit After Tax Growth (1y)PAT Growth (1y) | 4,048.85% | 15.30% | 47.96% | 44.97% | -101.54% | 19.62% | 31.40% | -27.91% | |||
| Profit After Tax Growth (3y)PAT Growth (3y) | 7.99% | ||||||||||
| Profit After Tax (QoQ)PAT (QoQ) | -10.07% | -77.59% | 14.42% | 2,460.58% | -102.36% | -9.12% | 9.51% | 33.84% | -23.04% | 6.87% | |
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | -3.41% | -35.77% | -37.40% | -39.79% | -45.02% | ||||||
| Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) | -9.55% | -9.87% | -10.55% | -11.92% | -11.85% | -13.31% | |||||
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | -0.08M | -0.09M | 0.00M | ||||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | 0.02M | 0.00M | -0.09M | -762.00 | -685.00 | ||||||
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | 0.01M | 0.01M | 0.00M | ||||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | 0.00M | 0.00M | 0.01M | -836.00 | -835.00 | ||||||
| Return on Equity [ROE] Growth (1y)ROE Growth (1y) | 0.25M | -0.16M | -0.11M | -0.17M | |||||||
| Return on Equity [ROE] (QoQ)ROE (QoQ) | 0.24M | -0.06M | 0.03M | 0.04M | -0.17M | -0.01M | -0.03M | ||||
| Return on Invested Capital [ROIC] Growth (1y)ROIC Growth (1y) | 0.01M | 0.01M | 0.00M | ||||||||
| Return on Invested Capital [ROIC] (QoQ)ROIC (QoQ) | 0.00M | 0.00M | 0.01M | -859.00 | -895.00 | ||||||
| Return on Sales [ROS] Growth (1y)ROS Growth (1y) | -2.31M | 1.86M | -4.45M | 15.88M | 0.90M | 4.03M | -0.75M | ||||
| Return on Sales [ROS] Growth (3y)ROS Growth (3y) | 12.82M | ||||||||||
| Return on Sales [ROS] (QoQ)ROS (QoQ) | 9.93M | 3.31M | 14.09M | -3.00M | -0.89M | 0.14M | |||||
| Revenue Growth (1y) | 233.33% | -93.88% | 1,200.00% | ||||||||
| Revenue (QoQ) | 296.67% | 1,273.11% | |||||||||
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | -54.59% | -53.60% | -61.70% | -94.00% | 7.08% | -8.01% | |||||
| Share-based Compensation (QoQ)Stock Comp. (QoQ) | -1.58% | -0.47% | 621.81% | -93.58% | 0.57% | -17.84% | 13.06% | 14.62% | -13.61% | ||
| Total Debt Growth (1y) | 77.57% | ||||||||||
| Total Debt (QoQ) | 0.63% | 0.64% | 0.64% |
Pull Inhibrx Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=INBX&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "INBX", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=INBX&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();